Dr. Ken Anderson is the Kraft Family Professor of Medicine at Harvard Medical School, as well as Director of the LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute. He trained in internal medicine at Johns Hopkins Hospital, and then completed hematology, medical oncology, and tumor immunology training at the Dana-Farber Cancer Institute. He is a Doris Duke Distinguished Clinical Research Scientist and American Cancer Society Clinical Research Professor. Over the last four decades, he has developed laboratory and animal models of multiple myeloma in its microenvironment which have allowed for both identification of novel targets and validation of novel targeted and immune therapies. He has then led efforts to rapidly translate these studies to clinical trials culminating in FDA approval of multiple novel targeted therapies, which have transformed the treatment paradigm and markedly improved patient outcome. He has also trained generations of researchers and caregivers who are now leading myeloma centers internationally. He has received the American Society of Hematology William Dameshek Prize, the American Association for Cancer Research Joseph H. Burchenal Award, the American Society of Clinical Oncology David A. Karnofsky Award, and the Harvard Medical School Warren Alpert Prize. He is also recipient of the Robert A. Kyle Lifetime Achievement Award from the International Myeloma Foundation and the Waldenstrom Award at the International Myeloma Workshop. He is a Fellow of the American Association for Cancer Research Academy and the American Society of Clinical Oncology, a member of the National Academy of Medicine as well as Royal College of Physicians and Pathologists, and past President of the International Myeloma Society and American Society of Hematology.
